Please login to the form below

Not currently logged in

GalbraithWight appoints Eithne McShane and Steve Mazzarese

They join the market access consultancy as global business development directors

GalbraithWight Eithne McShaneGalbraithWight has appointed Eithne McShane and Steve Mazzarese as global business development directors.

McShane (pictured right) brings experience to the role from Bayer, where she served as market access manager, Novartis Oncology and Therabel Europe.

In her new role at UK-based market access consultancy she will be tasked with growing GalbraithWight's business with global and regional clients located in Europe.

GalbraithWight Steve MazzareseGalbraithWight's other new global business development director, Steve Mazzarese (pictured left), will be based in New Jersey in the US.

He previously served with Wolters Kluwer, Cegedigm and IMS, and in his new role will be responsible for GalbraithWight's new launch excellence planning application Apollo LX.

The web-based application aims to provide global visibility and control of brand launches across the enterprise to improve communication between functions as well as between a company's headquarters and the various countries in which it operates.

Also joining GalbraithWight are senior consultant and account manager Ilsu Labat-Camy, senior consultant Lup Yee Yau, senior consultant Andrea Schatke, they will be based in Paris, the south east UK and Vienna respectively.

The consultancy has also appointed Julie Green and Vittoria de Ghislanzoni-Cardoli as project support managers to its Milan office and in the UK promoted Mel Dearing to project support manager.

18th January 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?